Ukwehlula Umdlavuza Nge-CAR T Cell Therapy ENdiya

Thola ithemba nokuphulukiswa nge-CAR T Cell Therapy eNdiya.

Thintana, futhi sizokuxhumanisa nezibhedlela eziphezulu e-India zokwelashwa kwe-CAR T-Cell.

Izinkampani ezifana ne-Immunoact, Cellogen ne-Immuneel ziyakha I-CAR T cell therapy eNdiya. I-India inake kakhulu ukwelashwa kwe-CAR T-cell, okuwuhlobo olusha lwe-immunotherapy. Kulokhu kwelashwa okusha, amasosha omzimba esiguli ahlelwa kabusha ukuze athole futhi abulale amangqamuzana omdlavuza. Eminyakeni embalwa edlule, izibhedlela zaseNdiya nezikhungo zokufunda sezihambe ibanga elide ekusebenziseni i-CAR T-cell therapy. Ukwelashwa kwe-CAR T-cell kungashintsha indlela umdlavuza olashwa ngayo, ngakho kunikeza iziguli ezingenakho okunye ukukhetha okuningi ithemba elisha. Kunezinhlelo zokudala nokwenza I-CAR T-cell therapy eNdiya, obekungenza kube lula ukutholakala futhi kushibhile.

I-CAR T-Cell Therapy E-India - Isimo Samanje

NgoFebhuwari, i-2024: Ngo-Okthoba 2023, i-Central Drugs Standard Control Organisation CDSCO), elingana ne-India ne-US Food and Drug Administration, yanikeza imvume kwa-NexCAR19, okuyenze kwaba ukwelapha kweseli lokuqala le-CAR-T ukuthi linikezwe ilayisense e-India. Ukwelashwa kwe-CAR T Cell eNdiya yethulwe ngokusemthethweni ezibhedlela eziyisi-6 kulo lonke elaseDelhi, eMumbai nasePune.

Ilayisense yanikezwa ngokusekelwe kulokho okutholwe ezinhlolweni ezimbili zomtholampilo ezilinganiselwe ezenziwa e-India ezibandakanya isamba sabantu abangama-64 abatholakala bene-lymphoma ethuthukisiwe noma i-leukemia. Ngokusekelwe emiphumeleni yocwaningo eyanikezwa emhlanganweni we-American Society of Hematology ngoDisemba 2023, kwabonakala ukuthi ama-67% eziguli (36 kwezingama-53) ezibambe iqhaza ocwaningweni olubili ahlangabezane nokuncipha okukhulu kobukhulu bomdlavuza wazo (impendulo yenhloso. ). Cishe isigamu salezi ziguli sathola ukunyamalala ngokuphelele kwesifo esibi (impendulo ephelele).

I-ImmunoACT, inkampani ephethwe yi-IIT Bombay, ihlinzeke ngezimali zokuhlola futhi izoba nesibopho sokukhiqiza nokudayisa i-actalycabtagene autoleucel.

Ezinye izikhungo zomdlavuza e-India seziqale ukwelashwa kwe-CAR T-Cell ye-DLBCL, BALL, Multiple Myeloma, Gliomas, isibindi, i-pancreas, ikholoni, umdlavuza wamaphaphu, womlomo wesibeletho kanye ne-GI ngosizo lwenkampani yaseMalaysia, ngaphandle kwezivivinyo zomtholampilo eziqhubekayo I-ACTREC kanye neNarayana, Bengaluru. Lezi zikhungo zihlinzeka ngokufakwa kwe-CAR T-Cells ngokubambisana ne-Malaysian Genomic Resource Centre. I-MGRC isebenzisane nenkampani yase-CAR Cell biotech yaseChina ukuletha Ukwelashwa kwe-CAR T-Cell eNdiya. Kulokhu kwelashwa, iziguli amaseli amhlophe egazi akhishwa, bese i-chimeric agent receptor (CAR) idluliselwa kuma-T-Cells. Ngale nqubo, amaseli esiguli athuthelwa esikhungweni se-biotech e-Malaysia. Lawa maseli e-CAR-T abe esebuyiselwa esigulini. Lawa maseli acutshunguliwe abopha namaseli omdlavuza futhi awabulale.

I-CAR T-Cell etshalwe ekhaya ikhula ngesivinini esikhulu eNdiya. Ngemuva kwezimvume kukholakala ukuthi Ukwelashwa kwe-CAR T-Cell e-India kuzobiza kancane njenge-$20,000 USD. Izibhedlela e-India, okuyi-Tata Memorial, Narayana, Bengaluru, & CMC, Vellore, seziqalile ukuvivinya. Lokhu kuzosindisa izimpilo zamakhulu eziguli ezilwa nohlobo oluthile lomdlavuza wegazi. Njengamanje, lokhu kwelashwa okusindisa impilo kuyatholakala e-USA, UK, Canada, Israel, Singapore, China, Malaysia, nase-Australia. Maduze nje, izotholakala naseNdiya, eNingizimu Korea naseJapane. Izindleko zalokhu kwelashwa ziseduze 5-7,00,000 USD e-USA, kanti e-China kubiza noma kuphi phakathi $70,000 futhi $80,000 USD.

Izilingo zomtholampilo ze Ukwelashwa kwe-CAR T- Cell ukwelapha ezinye izinhlobo zomdlavuza wegazi kuqale e-Advanced Center for Treatment, Research and Education in Cancer uphiko locwaningo nokuthuthukiswa kwe-Tata Memorial Centre. "Eminye imininingwane yecala izodalulwa maduze," kusho uDkt. Narula esithangamini sabezindaba. Lolu cwaningo lomtholampilo lwenziwa ngosizo lomcwaningi wakwa-IIT, e-Bombay osungule lolu hlelo lokwelapha olusindisa impilo.

I-Dr Reddys lab iphinde yathola isivumelwano ne-Shenzen Biopharma Pregene yase-China ngenyanga kaMeyi, zingama-21 zokuletha lolu hlelo lokusindisa impilo eNdiya. Kukhona nezinye izinkampani eziningana ezisebenzela ukuletha lobu buchwepheshe eNdiya. Udokotela we-oncologist wase-India ozinze e-US uDkt. Siddharth Mukherjee ubese-India muva nje futhi ube nomhlangano no-Kiran Mazumdar Shaw we-Biocon & Mr. Kush Parmar we-5 AM ventures. Bonke sebevumelene ngokuqhamuka nesikhungo sokukhulisa amaseli eChimeric Antigen Receptor (CAR) ukulwa nomdlavuza. Njengokwemibiko, lokhu kwelashwa kungatholakala eNdiya esikhathini esingangonyaka. Lokhu kwelashwa kusanda kugunyazwa ngabakwa FDA (Ukuphathwa kokudla nezidakamizwa). Lokhu kwelashwa ngamaseli kuyasiza ekwelapheni izingane ezithile kanye nabantu abadala abasebasha abaphethwe i-Non - Hodgkin lymphoma. Ukwelashwa nge-Yeskarta & Kymriah kungokokuqala Ukwelashwa kwe-CAR T-Cell ukwamukela FDA ukuvunywa.

Ngaphandle kokuthi kunezivivinyo eziningi zokwelashwa kwamaseli ezisebenzayo futhi ezibhalisayo e-United States, e-European Union naseChina, azikho ezitholakele eNdiya.

Isikhungo esisha se-Immuneel e-Bengaluru's Narayana Health City sinikezelwe ekwethuleni ama-cell therapies ekhwalithi ephezulu futhi athengekayo e-India. Indawo ekahle yalesi sikhungo esibhedlela sokunakekelwa kwemfundo ephakeme eduze neyunithi yokufakelwa komnkantsha enevolumu ephezulu ivumela ukusebenzelana okwengeziwe phakathi kwamaqembu ocwaningo nabelaphi, okubalulekile ekuthuthukisweni komtholampilo okugxilile kwezindlela zokwelapha eziqanjiwe eziqondene nawe njenge-CAR-T.

I-Immuneel isebenza kanzima ukuthuthukisa ipayipi layo. Isu lenkampani lokunikeza ilayisense kwempahla ye-CAR-T esesivele ihloliwe kulindeleke ukuthi iphumele esivivinyweni sokuqala senkampani sokwelashwa kwamaseli ngo-2021. Mayelana nelabhorethri nezindawo zokukhiqiza, okuhlanganisa imishini namathuluzi, indawo edidiyelwe ye-Immuneel iphakathi kwe best emhlabeni. Lokhu kusiza odokotela nososayensi ukuthi basebenze ndawonye ngaphandle komthungo ngaphakathi kanye nezikhungo zocwaningo emhlabeni wonke ekudalweni nasekusabalaliseni umkhiqizo. Ukuze kusekelwe lokhu okuhlosiwe, inhlangano ihehe ithalente lomhlaba jikelele elinolwazi lwangaphambili ekwelapheni kwamaseli, kanye neBhodi Lokweluleka Ngesayensi elihlukile elihlanganisa iziqhwaga ezihlonishwa kakhulu zesayensi nezobuhlakani.

Lezi zindlela zokwelapha zisebenza kanzima, zilawulwa ngokucophelela, zidinga ama-reagents / izinto ezibizayo, futhi kunzima ukuzisebenzisa. Ukuphathwa kokulondolozwa nokuthuthwa kwamaseli agcinwe ngokuqhubekayo kuyinkinga yomhlaba wonke. Ngenxa yazo zonke lezi zinto, ukwelashwa kwamaseli kunzima kakhulu ukukhiqiza nokunikezela, ngakho-ke kubiza ngokweqile. Ukwelashwa kwamaseli kunzima ukukunika imitholampilo, futhi iziguli kufanele zibhekwe ngeso elibukhali ngemicimbi emibi esibhedlela ngokushesha ngemuva kokumunyelwa.

Umphumela Wesigaba II CAR T-Cell Therapy Clinical Trials ENdiya

Engqungqutheleni ye-ASCO, ngoDisemba 22, i-Immuneel, isiqalo sokwelashwa kwamaseli nofuzo, umemezele ukuthi imiphumela yokuqala evela ezivivinyweni zomtholampilo zase-India zesigaba sokuqala sesibili kukhombisa izinga lokuphendula lilonke elingama-2% ezinsukwini ezingama-77 ezigulini ezinomdlavuza wegazi njenge-leukemia ne-lymphoma. I-Immuneel yenza i-CAR-T cell therapy i-Varnimcabtagene.

Okutholwe kokuqala okuvela ocwaningweni lwe-IMAGINE kwakusekelwe ekubhalisweni kwabantu bokuqala abayi-10 ezigulini ezingama-24 sezizonke.
Ngosuku lwama-28, ngaphezu kwe-80% yeziguli zalulama ngokugcwele emtholampilo. Ngosuku lwe-90, idatha ye-IMAGINE yembule inani lokuphendula eliphelele lama-77%, nezimpendulo eziphelele ziboniswa ku-6 kwezingu-9 iziguli ezihlolekayo.

Ukufundwa kweziguli ze-B acute lymphoblastic leukemia ngosuku lwama-28 nosuku lwama-90 kukhombisa ukukhululwa okuphelele okungama-100% kanye nama-83%, ngokulandelana, okubonisa izimpendulo ezisheshayo, ezinamandla nezihlala isikhathi eside.

I-Varnimcabtagene ithathe izinsuku ezingu-12 ngokwesilinganiso ukukhiqiza nokukhulula, ngezinga lempumelelo yokukhiqiza engu-100%.

U-Kiran Mazumdar-Shaw, usihlalo we-Biocon, uSiddhartha Mukherjee, udokotela odumile we-oncologist nombhali, kanye no-Kush Parmar, uzakwethu ophethe we-5AM Venture, owasungula u-Imuneel. I-Imuneel ithuthukisa ipayipi layo le-chimeric antigen receptor T-cell (CAR-T) zokwelapha kanye namanye ama-immunotherapies amaselula okwelapha umdlavuza.

Iyini Ububanzi BeCar-T Cell Therapy ENdiya?

Isingeniso: I-CAR T- cell therapy wuhlobo olusha lokwelapha olushintsha indlela umdlavuza olashwa ngayo emhlabeni wonke. Eminyakeni embalwa edlule, i-India yenze inqubekelaphambili enkulu ekwamukeleni lokhu kwelashwa okuphambili, inika iziguli ezinezinhlobo ezahlukene zomdlavuza izizathu ezintsha zokuba nethemba. Ukwelashwa ngamaseli e-CAR-T kungenzeka kube nomthelela omkhulu ekunakekelweni kwezempilo kwamaNdiya ngoba kungashintsha indlela umdlavuza olashwa ngayo.

Ukwandisa Izinketho Zokwelashwa: Ukufika kwe-CAR-T cell therapy e-India kunike iziguli izindlela eziningi zokwelapha, ikakhulukazi lezo ezinomdlavuza wegazi njenge-leukemia ne-lymphoma. Lokhu kwelashwa kuhilela ukukhipha ama-T cell esiguli, ukuwashintsha ngokofuzo ukuze akhiqize ama-chimeric antigen receptors (ama-CAR) aqondise amangqamuzana omdlavuza, bese ewabuyisela emzimbeni wesiguli. I-CAR-T cell therapy yindlela yomuntu siqu eyenza kube lula ukuthi amasosha omzimba athole futhi abulale amangqamuzana omdlavuza.

Ucwaningo kanye nokuthuthukisa: I-R&D isihambe ibanga elide. I-India ingqalasizinda eqinile yocwaningo nentuthuko, futhi izikhungo eziphezulu nezibhedlela zibheka ngenkuthalo amandla okwelashwa kwamaseli e-CAR-T. Lokhu kuzinikela ocwaningweni kuye kwaholela entuthukweni entsha ethokozisayo, njengokwakhiwa kwezindlela zokwelapha zamangqamuzana e-CAR-T eziklanyelwe ukuhlukahluka kwezakhi zofuzo kanye nezinhlanga eziyingqayizivele zabantu baseNdiya. Lezi zinhlobo zokuthuthukiswa zisiza ekwandiseni ukufinyelela kokwelashwa futhi kwenze kube nokwenzeka ukukusebenzisa ezinhlotsheni eziningi zomdlavuza.

Ukufinyeleleka nokufinyeleleka: Enye yezinto ezinhle kakhulu ngokwelashwa kwamaseli e-CAR-T e-India ukuthi, uma kuqhathaniswa namanye amazwe aseNtshonalanga, iyathengeka kakhulu. Iziguli ezivela kuzo zonke izizinda zempilo zisemathubeni amaningi okuthi zikwazi ukuyikhokhela ngoba amanani entengo aphansi futhi ziningi izinketho zokwelashwa. Futhi, izibhedlela eziningi zaseNdiya nezikhungo zezokwelapha zisebenze nezinkampani zezidakamizwa zamazwe ngamazwe ukuletha ukwelashwa kwamaseli e-CAR-T eNdiya, okwenza kube lula kubantu abakudingayo ukuthi bakuthole.

Izinselele kanye namathemba esikhathi esizayo: Ukwelashwa kwamaseli e-CAR-T kunamandla amaningi, kodwa futhi kunezinkinga ezithile. Ezinye zezinkinga okudingeka zixazululwe izindleko zokwelashwa ezimba eqolo, ubunzima bokwenza umuthi, nesidingo semishini ekhethekile. Kodwa uhulumeni waseNdiya, usebenzisana nababambiqhaza bezokunakekelwa kwempilo, usebenza kanzima ukuxazulula lezi zinkinga futhi umise uhlelo lokulawula ukuze ukwelashwa kusetshenziswe ngendlela ephephile nephumelelayo.

Ukusetshenziswa kwe-CAR-T cell therapy eNdiya kukhula ngokushesha, kunikeza iziguli ezinomdlavuza ithemba elisha nezindlela ezingcono zokwelapha isifo sazo. I-India iyindawo enhle yalokhu kwelashwa okuyisisekelo ngoba izibophezele ekufundeni, amanani aphansi, futhi ukufinyelela kuba ngcono. Njengoba uhlelo lwaseNdiya lokunakekelwa kwezempilo luqhubeka nokushintsha, ukwengezwa kokwelashwa ngamaseli e-CAR-T cishe kungase kuguqule indlela umdlavuza olashwa ngayo, kwenze izinto zibe ngcono ezigulini futhi kushintshe ukuphila.

Uhlolojikelele Ngamathuba Okwelapha Amaseli E-CAR T ENdiya

Eminyakeni yamuva nje, i-India iye yavela njengenkanyezi eqondisayo yethemba leziguli ezinomdlavuza ezifuna ukwelashwa okuthuthukisiwe okufana Ukwelashwa kwe-CAR T Cell eNdiya. I-CAR T Cell Therapy iyindlela eyinguquko ekwelapheni umdlavuza. Iqondise futhi iqede amangqamuzana omdlavuza ngokusebenzisa amasosha omzimba.

Lokhu kuyenza ibe inketho ethembisayo ezigulini eziningi ezinomdlavuza, njengoba inemiphumela engemihle embalwa uma iqhathaniswa nokwelashwa kwendabuko. Ungathola lokhu kwelashwa okusha ezikhungweni ezimbalwa ezivelele zokunakekelwa kwezempilo zaseNdiya, njenge-Tata Memorial Centre, i-Apollo Cancer Hospital, i-BLK, i-Artemis, i-Asian Oncology, i-American Oncology, ne-HCG.

Ukutholakala kwe-CAR T Cell Therapy kulezi zikhungo zezempilo ezihlonishwayo kuyisinyathelo esikhulu ekulweni nomdlavuza waseNdiya. Thola izibhedlela ezi-5 eziphezulu ezaziwa ngokuhlinzeka okungcono kakhulu Ukwelashwa kwe-Car T eNdiya.

Isibhedlela i-Tata Memorial Cancer eMumbai

Phakathi kwabahlinzeki abahamba phambili be I-CAR T Ukwelashwa ENdiya, kuqala igama lesibhedlela i-Tata Memorial, esihlinzeka ngemithi yokwelapha umdlavuza esezingeni lomhlaba. Kulesi sibhedlela, ithimba lodokotela abanolwazi nabacwaningi basebenza kanzima ukulwa nomdlavuza besebenzisa izindlela zokwelapha ezithuthukisiwe. Lesi sibhedlela saziwa ngokwenza kahle ekunakekelweni komdlavuza futhi sinolwazi olunzulu lokusebenzisa i-CAR T Cell therapy ukusiza iziguli zibe ngcono. Abantu beza lapha bevela ezindaweni zonke ngoba bethemba ukuthi i-Tata Memorial izobanika ithuba elihle lokunqoba umdlavuza. Ngakho-ke, uma wena noma othile omaziyo edinga ukunakekelwa okuhle kakhulu komdlavuza, i-Tata Memorial Cancer Hospital iyisinqumo esihle.

I-Apollo Cancer Institute e-Chennai

I-Apollo Cancer Institute e-Chennai isikhungo sezempilo esaziwa kakhulu ngezinsizakalo zaso ezinhle kakhulu zokwelapha umdlavuza. Banikeza ukunakekelwa okuphelele ezigulini ezinomdlavuza ngokusebenzisa ubuchwepheshe obuthuthukisiwe kanye neqembu elinolwazi olunzulu lodokotela be-oncologists. Ithimba labo elizinikele lodokotela be-oncologists, odokotela abahlinzayo, nabasebenzi abasekelayo basebenza ngokuzikhandla ukuze benze izinhlelo zokwelashwa eziqondene nawe ezibeka kuqala ukusebenza kahle kanye nezinga lempilo lesiguli. Ukuzinikela kwabo ekwenzeni kahle kubenzele idumela elihlonishwayo emkhakheni wokunakekelwa komdlavuza.

I-National Cancer Institute (AIIMS) eDelhi

I-National Cancer Institute (AIIMS) eDelhi ingesinye isikhungo esihamba phambili se-CAR-T cell therapy. Ungathola ukufinyelela ekwelashweni kwe-CAR-T lapha ngezindleko ezingabizi kakhulu. Lesi sikhungo sezokwelapha saziwa kakhulu ngocwaningo lwaso oluthuthukile lwe-immunoadoptive cell therapy, izikhungo ezisezingeni eliphezulu, nodokotela abanekhono eliphezulu. Lesi sikhungo sithatha indlela yethimba, sihlanganisa odokotela abangongoti bezempilo abanolwazi, odokotela abahlinzayo, odokotela bemisebe ye-radioologist, kanye nabasebenzi abasekelayo ukuze benze izinhlelo zokwelashwa eziqondene nawe zomdlavuza wegazi kanye nazo zonke ezinye izinhlobo zomdlavuza. Baze basebenzise nobuchwepheshe obuthuthukisiwe njengobuhlakani bokwenziwa kanye nokuhlaziywa kofuzo ukuze banikeze ukunakekelwa okungcono kakhulu komdlavuza ezigulini.

I-BLK Max Cancer Centre, eDelhi

I-BLK Max Cancer Centre eDelhi ingesinye sezibhedlela zomdlavuza ezihamba phambili e-India, esizinikezele ekuhlinzekeni i-chimeric antigen receptor t cell therapy (CAR T). Isikhungo sabo sinobuchwepheshe obuthuthukile bokunakekelwa komdlavuza okubandakanya ukuhlinzwa ngamarobhothi, i-tomo therapy, kanye ne-immunotherapy. Indawo yabo efudumele nesekelayo ingakusiza uhlale uqinile futhi ulwe nesifo.

I-Rajiv Gandhi Cancer Institute & Nesikhungo Sokucwaninga eDelhi

I-Rajiv Gandhi Cancer Institute & Research Center eDelhi ingesinye sezikhungo zomdlavuza ezihamba phambili e-Asia. Ubuchwepheshe babo obusha kanye nabasebenzi abanamakhono banikeza ukunakekelwa komdlavuza osezingeni lomhlaba ezigulini zaseNdiya, kanye nasezizweni ze-SAARC. Lesi sikhungo sibe nelungelo lokuba nomthelela omuhle ezimpilweni zeziguli ezinomdlavuza ezilinganiselwa ku-2.75 lakh kusukela sasungulwa ngo-1996. Uchwepheshe wabo unikeza ukunakekelwa okungcono kakhulu ezigulini ezinomdlavuza ngokwelashwa okungabizi kakhulu kwe-CAR T Cell eNdiya.

Hlangana Nama-Oncologists Aphezulu Okwelapha Amaseli E-CAR T ENdiya

Funda ngama-oncologists aphezulu I-CAR T Ukwelashwa ENdiya. Labo dokotela abanolwazi bazibophezele ekuhlinzekeni ukwelashwa kwamaseli okungcono kakhulu komdlavuza kanye nokunakekelwa komuntu siqu kanye nokwesekwa. Thembela kulwazi lwabo ukuze uthole ikusasa eliqhakazile ekulweni kwakho nomdlavuza!

UDkt T Raja (MD, DM)

UDkt. T Raja uyi-Medical Oncologist owaziwayo oneminyaka engaphezu kwengu-25 yokuhlangenwe nakho ekwelapheni umdlavuza. Waziwa kakhulu ngolwazi lwakhe oluvelele futhi uthathwa njengomunye wochwepheshe be-oncology abaphambili baseNdiya. UDkt. Raja futhi unesikhundla esivelele sezemfundo, ehola uhlelo lwe-DNB Medical Oncology esibhedlela i-Apollo Specialty e-Chennai. Uyisikhulumi esifunwa uthuli ezingqungqutheleni zikazwelonke nezamazwe ngamazwe, lapho abelana khona ngemibono yakhe ebalulekile.

UDkt Srikanth M (MD, DM)

UDkt. Srikanth M. ungudokotela wegazi onolwazi olunzulu e-Chennai, owaziwa ngobungcweti bakhe ekwelapheni izimo ezihlukahlukene ezihlobene negazi. Usebenza ngokukhethekile kuzo zombili izindaba zezempilo zesikhashana nezesikhathi eside njenge-anemia, i-myeloma, i-b-cell lymphomas kanye ne-leukemia. UDkt. Srikanth M. futhi uhlinzeka ngokuhlolwa okuthuthukisiwe ukuhlola impilo yakho iyonke, njenge-bone marrow aspiration kanye nokwelashwa kwe-chelation ezimweni ezingavamile njengokudlulela kwamaminerali egazini. UDkt. Srikanth M. uthole imiklomelo ngeqhaza lakhe ocwaningweni lwe-myeloma, okumenza uchwepheshe othembekile we-hematology olungele ukunikeza ukunakekelwa okukhethekile ezigulini ezidingayo.

UDkt Revathi Raj (MD, DCH)

UDkt. Revathi Raj unguchwepheshe ohlonishwa kakhulu owaziwa ngobungcweti bakhe ekufakweni komnkantsha wezingane. Uqhube ngempumelelo ngaphezu kuka-2000 kwalokhu kufakelwa, okumenza uchwepheshe ohamba phambili waseNdiya. UDkt. Raj unokuhlangenwe nakho okukhulu kokwelapha izingane ezinegazi elingavamile njenge-thalassemia, i-hemophilia, i-sickle cell anemia, i-aplastic anemia, ne-leukemia. Uzibophezele kakhulu enhlalakahleni yezingane, uqhuba insizakalo eyisipesheli ye-leukemia yezingane kanye ne-lymphoma enezinga lokwelapha elingama-80%.

Izindleko Zokwelapha I-Car T-Cell ENdiya

Ngo-Okthoba 13, 2023, inkampani ebizwa nge-Immunoadoptive Cell Therapy Private Limited (ImmunoACT) eMumbai yathola imvume evela ku-Central Drugs Standard Control Organisation (CDSCO) yokwelashwa okukhethekile komdlavuza e-India okubizwa nge-NexCAR19.

Lokhu kwelashwa kuklanyelwe ngokukhethekile ukusiza abantu abanezinhlobo ezithile ze-leukemia ne-lymphoma abangakaphenduli kwezinye izindlela zokwelapha. Ukuhlolwa komtholampilo kwale nqubo kwenziwa ezigulini ezingama-60 ezine-lymphomas ne-leukamia. Isilinganiso sokuphendula esiphelele salolu cwaningo lomtholampilo olubalulekile lwalungama-70% oluluphawule njengokwelapha okuphumelelayo ukubhubhisa amangqamuzana omdlavuza ngempumelelo kakhudlwana.

The izindleko zokwelashwa kwe-CAR T cell eNdiya cishe i-USD 57,000. Le ntengo iphansi kakhulu uma uyiqhathanisa namazwe afana neChina. Kodwa-ke, kubalulekile ukuqaphela ukuthi le ntengo ingahluka ngokuya ngezinto ezahlukahlukene. Izindleko zokwelashwa kwamaseli e-CAR-T zingase zehluke kusukela kwesinye isibhedlela kuye ngobuchwepheshe babo, ubuchwepheshe, nezinye izinsiza.

Ngaphezu kwalokho, uhlobo lokwelashwa kwe-CAR T-cell oludingekayo kanye nesimo sesiguli kungase kuthinte izindleko zizonke. Amabhizinisi aseNdiya afana ne-Immunoact, Immuneel, ne-Cellogen maduze azokwethula ezawo izindlela zokwelapha ze-CAR T-Cell, ezizobiza phakathi kuka-$30,000 no-$40,000. Njengomphumela, i-India izokleliswa phakathi kwezindawo ezinenani elizwakalayo zokwelapha i-CAR T-cell therapy.

Iyini I-Car T-Cell Therapy?

I-Chimeric antigen receptor T-cell therapy, evame ukwaziwa ngokuthi i-CAR T-cell therapy, iwukwelapha okugoqa phansi okushintshe ngokuphelele indlela yokwelapha umdlavuza. Inikeza iziguli ezinomdlavuza othile ithemba ebekade libhekwa njengengelapheki noma kunezinye izindlela zokwelapha ezimbalwa.

Ukwelashwa kuhlanganisa ukusebenzisa amaseli omzimba esiguli—ikakhulukazi, ama-T cell—kanye nokuwashintsha ilebhu ukuze kuthuthukiswe amandla awo okuthola nokucekela phansi amangqamuzana omdlavuza. Ukwenza lokhu, ama-T cell anikezwa i-chimeric antigen receptor (CAR), ewanikeza amandla okukhomba amaprotheni athile, noma ama-antigen, ebusweni bamaseli omdlavuza.

Ama-T cell esiguli aqale akhishwe, bese eshintshwa izakhi zofuzo ukuze aveze i-CAR. Elabhorethri, la mangqamuzana ashintshiwe ayaphindaphindeka ukuze akhiqize inani elikhulu lamaseli e-CAR T, abese ebuyiselwa egazini lesiguli.

Ngokushesha nje lapho engaphakathi emzimbeni, amaseli e-CAR T athola amangqamuzana omdlavuza aveza i-antigen oyifunayo, anamathisele kuwo, futhi aqalise ukusabela okunamandla kokuzivikela komzimba. Amaseli e-CAR T acushiwe ayanda futhi ahlasele amangqamuzana omdlavuza, awabulale.

Uma isetshenziselwa ukwelapha izifo ezithile zegazi njenge-acute lymphoblastic leukemia (ALL) kanye nezinhlobo ezithile ze-lymphoma, ukwelashwa kwe-CAR T-cell kubonise imiphumela engavamile. Ikhiqize izilinganiso zokusabela eziphawulekayo futhi kwezinye iziguli, ngisho nokukhululwa okuhlala isikhathi eside.

I-CAR T-cell therapy, nokho, iyindlela yokwelapha eyinkimbinkimbi neyingqayizivele engase ibe nezingozi nemiphumela emibi. I-Cytokine release syndrome (CRS), ukusabela kwe-immunology okusabalele okungase kubangele izimpawu ezifana nomkhuhlane futhi, ezimweni ezimbi kakhulu, ukwehluleka kwezitho, kungase kutholwe abantu abathile. Kubuye kube nemibiko yemiphumela emibi yemizwa, nokho ivamise ukulapheka.

Naphezu kwalobu bunzima, ukwelashwa kwe-CAR T-cell kuyintuthuko ebalulekile ekulweni nomdlavuza futhi kukhombisa amandla amakhulu ekusasa. Ucwaningo lwamanje lugxile ekuthuthukiseni ukusebenza kwayo kanye nephrofayili yokuphepha kanye nokwelula ukusetshenziswa kwayo ezinhlotsheni zomdlavuza ezihlukene. I-CAR T-cell therapy inamandla okushintsha ubuso bokwelashwa komdlavuza futhi inikeze iziguli yonke indawo ithemba elisha ngentuthuko eyengeziwe.

Lolu hlobo lokwelapha lubandakanya ukulungisa ama-T cell esiguli, uhlobo lwamangqamuzana omzimba omzimba, elebhu ukuze abophe futhi abulale amangqamuzana omdlavuza. Ishubhu lithutha igazi lisuka emthanjeni osengalweni yesiguli liye emshinini obizwa ngokuthi i-apheresis (ongabonisiwe), okhipha amangqamuzana amhlophe egazi, kuhlanganise nama-T cell, bese ubuyisela igazi elisele esigulini.

Amaseli e-T abe eseshintshwa ngofuzo elebhu ukuze aqukathe ufuzo lwesamukeli esiyingqayizivele eyaziwa ngokuthi i-chimeric antigen receptor (CAR). Amaseli e-CAR T aphindaphindeka elebhu ngaphambi kokuthi afakwe esigulini ngamanani amakhulu. I-antigen emangqamuzaneni omdlavuza ingabonwa ngamaseli e-CAR T, abese ebulala amangqamuzana omdlavuza.

Inqubo

Inqubo yokwelapha i-CAR-T, ethatha amasonto ambalwa, ibandakanya izinyathelo eziningi:

Ama-T cell akhishwa egazini lakho kusetshenziswa ishubhu elifakwa emthanjeni wengalo. Lokhu kuthatha amahora ambalwa.

Ama-T cell athuthelwa endaweni lapho enza khona ukuguqulwa kofuzo ukuze abe amaseli e-CAR-T. Kudlula amasonto amabili kuya kwamathathu kukho konke lokhu.

Amangqamuzana e-CAR-T abuyiselwa egazini lakho nge-drip. Lokhu kudinga amahora ambalwa.

Amaseli e-CAR-T aqondisa futhi aqede amangqamuzana omdlavuza kuwo wonke umzimba. Ngemva kokuthola ukwelashwa kwe-CAR-T, uzobhekwa eduze.

Hlobo Luni Lwamaseli Omdlavuza Angelashwa NgeCar-T Cell Therapy?

Iziguli kuphela ezine-B-cell non-lymphoma Hodgkin's noma i-pediatric acute lymphoblastic leukemia esezizame izindlela zokwelapha ezivamile ezimbili ezingaphumelelanga okwamanje ezingasebenzisa imikhiqizo yokwelapha ye-CAR T-cell ethole imvume ye-FDA. Kodwa-ke, ukwelashwa kwe-CAR T-cell manje kuyahlolwa ezifundweni zomtholampilo njengokwelashwa komugqa wokuqala noma wesibili we-lymphoma yabantu abadala kanye ne-acute lymphoblastic leukemia yezingane. Muva nje, ezinye zezifundo zibonise impumelelo emangalisayo ezimeni zezimila eziqinile ezifana ne-glioblastoma, i-gliomas, umdlavuza wesibindi, umdlavuza wamaphaphu, umdlavuza we-GI, umdlavuza we-pancreatic kanye nomdlavuza womlomo.

Ukuphetha

Lokhu kubonisa intuthuko enkulu ekulawuleni i-leukemia kanye ne-B-cell lymphoma. Ukwengeza, kunikeza ithemba kulabo okwabikezelwa ukuthi ukuphila kwabo kuzohlala izinyanga eziyisithupha kuphela. Manje njengoba sesihlonze izindlela zokumelana futhi sakha amasu amaningi okulwa nazo, ikusasa libonakala lithembisa kakhulu.

Thintana nabahlinzeki bethu bezempilo abanolwazi olunzulu lapha ku ICancerFax ukuze uthole ukubonisana kwamahhala ukuze wenze uhlelo lokunakekelwa olufanele lwezidingo zakho zezempilo. Sicela uthumele imibiko yakho yezempilo ku info@cancerfax.com noma ku-WhatsApp + 1 213 789 56 55.

Yiziphi Izinzuzo ZeCar-T Cell Therapy?

Inzuzo eyinhloko ukuthi ukwelashwa kwe-CAR T-cell kudinga kuphela ukumnika okukodwa futhi ngokuvamile kudinga kuphela amasonto amabili okunakekelwa kwesiguli. Iziguli ezine-non-Hodgkin lymphoma kanye ne-leukemia yezingane ezisanda kutholwa, ngakolunye uhlangothi, ngokuvamile zidinga ukwelashwa ngamakhemikhali okungenani izinyanga eziyisithupha noma ngaphezulu.

Izinzuzo zokwelashwa kwe-CAR T-cell, empeleni okuwumuthi ophilayo, zingaphikelela iminyaka eminingi. Uma futhi kwenzeka ukuphindeka, amaseli asazokwazi ukukhomba futhi aqondise amaseli omdlavuza ngoba angaphila emzimbeni isikhathi eside.

Nakuba ulwazi lusathuthuka, u-42% weziguli ze-lymphoma zabantu abadala ezathola ukwelashwa kwe-CD19 CAR T-cell zazisenoshwele ngemva kwezinyanga eziyi-15. Futhi ngemva kwezinyanga eziyisithupha, izingxenye ezimbili kwezintathu zeziguli ezine-acute lymphoblastic leukemia zazisaxole. Ngeshwa, lezi ziguli zinezimila ezinolaka kakhulu ezingazange zilashwe ngempumelelo kusetshenziswa izindinganiso zendabuko zokunakekela.

Hlobo luni lweziguli ezingaba ngabamukeli abahle be-CAR-T Cell Therapy?

Iziguli ezineminyaka ephakathi kwemi-3 kuya kwengu-70 zizanyiwe nge-CAR T-Cell yokwelapha izinhlobo ezahlukene zomdlavuza wegazi futhi kutholakale ukuthi iyasebenza kakhulu. Izikhungo eziningi ziye zafuna amanani empumelelo angaphezu kuka-80%. Umuntu ongcono kakhulu wokwelashwa kwe-CAR T-cell ngalesi sikhathi yingane ene-acute lymphoblastic leukemia noma umuntu omdala one-B-cell lymphoma enamandla osevele enemigqa emibili yokwelapha okungasebenzi.

Ngaphambi kokuphela kuka-2017, lalingekho izinga elamukelekayo lokunakekela ezigulini esezidlule emigqeni emibili yokwelashwa ngaphandle kokuthola ukuxolelwa. Okuwukuphela kwendlela yokwelapha egunyazwe i-FDA kuze kube manje osekufakazele ukuthi kunenzuzo enkulu kulezi ziguli ukwelapha nge-CAR T-cell.

Isebenza Kangakanani I-Car-T Cell Therapy?

Ukwelashwa kwe-CAR T-cell kube yimpumelelo kakhulu ekwelapheni ezinye izinhlobo zomdlavuza wegazi, njenge-acute lymphoblastic leukemia (ALL) kanye ne-non-Hodgkin lymphoma. Ezivivinyweni zemitholampilo, amazinga okuphendula abe mahle kakhulu, futhi iziguli eziningi ziye zangena ekwelashweni okuphelele. Kwezinye izimo, abantu ababezame yonke eminye imithi baba nokukhululwa okuhlala isikhathi eside noma ngisho nokwelashwa okungenzeka.

Enye yezinto ezinhle kakhulu ngokwelashwa kwe-CAR T-cell ukuthi iqondise kumaseli afanele. Ama-receptor e-CAR angezwe kuma-T cell angathola amamaki athile kumaseli omdlavuza. Lokhu kwenza kube nokwenzeka ukunikeza ukwelashwa okuhlosiwe. Le ndlela ehlosiwe ilimaza amaseli anempilo kancane ngangokunokwenzeka futhi yehlisa ubungozi bemiphumela engemihle eza nokwelashwa kwendabuko okufana nokwelapha ngamakhemikhali.

Kodwa kubalulekile ukukhumbula ukuthi ukwelashwa kwe-CAR T-cell kuseyindawo entsha esashintsha. Abacwaningi nodokotela basebenza kanzima ukuxazulula izinkinga ezifana nezindleko eziphezulu, amathuba okuba nemiphumela emibi kakhulu, kanye neqiniso lokuthi kusebenza kuphela ezinhlotsheni ezithile zomdlavuza.

Ekugcineni, ukwelashwa kwe-CAR T-cell kubonise ukuthi kuyindlela ephumelela kakhulu yokwelapha ezinye izinhlobo zomdlavuza wegazi. Noma kuyindlela ethembisayo nenamandla, ucwaningo olwengeziwe nezivivinyo zomtholampilo ziyadingeka ukuze kuthuthukiswe futhi kutholwe izindlela ezintsha zokuyisebenzisa. Ukwelashwa kwe-CAR T-cell kungashintsha indlela umdlavuza welashwa ngayo futhi kwenze izinto zibe ngcono kubantu emhlabeni wonke uma uqhubeka nokuba ngcono.

Imibandela Yokufakwa Nokukhishwa

Umbandela Wokufaka Wokwelashwa Kwe-CAR T-Cell:

1. Iziguli ezine-CD19 + B-cell Lymphoma (Okungenani ama-regimens we-2 chemotherapy ngaphambi kokuhlanganiswa)

2.Ukuba neminyaka eyi-3 kuye kwengama-75

3. Isilinganiso se-ECOG ≤2

4. Abesifazane abanamandla okuthola izingane kumele babe nomchamo ukukhulelwa ukuhlolwa okwenziwe kwatholakala ukuthi une-negative ngaphambi kokwelashwa. Zonke iziguli ziyavuma ukusebenzisa izindlela ezithembekile zokuvimbela inzalo ngesikhathi sesilingo kuze kube kulandelwa okokugcina.

Imibandela Yokungafakwa Ye-CAR T-Cell Therapy:

1.Ukuphakama komfutho wegazi ophakeme noma ukuquleka

2. Ukwehluleka kokuphefumula

3. Kusatshalaliswe i-coagulation ye-intravascular

4. I-Hematosepsis noma ukutheleleka okusebenzayo okungalawulwa

5. Okungalawulwa isifo sikashukela

Yimiphi imiphumela emibi ye-Car-T Cell Therapy?

Okubalulwe ngezansi eminye yemiphumela emibi yokwelashwa kwe-CAR T-Cell.

I-Cytokine release syndrome (CRS): Umthelela oseceleni ovame kakhulu futhi okungenzeka ubaluleke kakhulu wokwelashwa kwe-CAR T-cell i-cytokine release syndrome (CRS). Izimpawu ezinjengomkhuhlane, okuhlanganisa imfiva, ukukhathala, ikhanda elibuhlungu, nobuhlungu bemisipha, zibangelwa ukukhiqizwa kwama-T cell ashintshiwe ama-cytokines. Ezimweni ezimbi kakhulu, i-CRS ingase ibangele izinga lokushisa eliphezulu, i-hypotension, ukwehluleka kwezitho, ngisho nemiphumela engase ibulale.
Ubuthi Bezinzwa: Ezinye iziguli zingase zibe nemiphumela engemihle yemizwa, engase ihluke kakhulu kusukela kuzimpawu ezingathí sina njengokudideka okuncane kanye nokudideka kuye kwezibucayi kakhulu njengokuquleka, ukudangala, kanye ne-encephalopathy. Ngemuva kokujova i-CAR T-cell, ubuthi bezinzwa buvame ukwenzeka phakathi nesonto lokuqala.
I-Cytopenias: Ukwelashwa kwe-CAR T-cell kungabangela ukubala okuphansi kwamangqamuzana egazi, njenge-anemia (isibalo esiphansi samangqamuzana egazi abomvu), i-neutropenia (isibalo esiphansi samangqamuzana egazi amhlophe), kanye ne-thrombocytopenia (isibalo esiphansi seplatelet). Ukutheleleka, ukopha, nokukhathala kuphakathi kwezingozi ezingabhebhethekiswa yilezi cytopenias.
Amagciwane: Ukucindezela kwe-CAR T-cell therapy kwamangqamuzana omzimba anempilo kwandisa ingozi yokutheleleka ngamagciwane, igciwane, kanye nesikhunta. Ukuze kuvinjwe izifo, iziguli kungase kudingeke ukuthi zibhekwe ngeso elibukhali futhi zinikezwe imithi yokuzivikela.
I-Tumor Lysis Syndrome (TLS): Ngemva kokwelashwa kwe-CAR T-cell, kwezinye izimo kuyenzeka ukuthi amanani amakhulu wokuqukethwe kweseli akhishelwe egazini ngenxa yokubulawa ngokushesha kwamaseli esimila. Lokhu kungase kubangele ukuphazamiseka kwezinqubo ze-metabolic, okufana namazinga e-potassium eningi, i-uric acid, ne-phosphate, okungase kulimaze izinso futhi kubangele nezinye izinkinga.
I-Hypogammaglobulinemia: Ukwelashwa kwe-CAR T-cell kunamandla okunciphisa ukwakheka kwe-antibody, okungase kubangele i-hypogammaglobulinemia. Lokhu kungase kwenze izifo eziphindelelayo zibe nokwenzeka kakhulu futhi kubize ukuqhubeka kwemithi yokubuyisela amasosha omzimba.
Ubuthi Bomzimba: I-CAR T-cell therapy inamandla okulimaza izitho eziningi, okuhlanganisa inhliziyo, amaphaphu, isibindi, nezinso. Lokhu kungase kuholele ekuhlolweni kokusebenza okungavamile kwezinso, izinkinga zokuphefumula, izinkinga zenhliziyo, nokuhlolwa kokusebenza okungavamile kwesibindi.
I-Hemophagocytic lymphohistiocytosis (HLH): Isifo esingandile kodwa esibulalayo esibizwa ngokuthi i-hemophagocytic lymphohistiocytosis (HLH) singakhula ngenxa yokwelashwa kwe-CAR T-cell. Kuhilela ukusebenza ngokweqile kwamangqamuzana omzimba omzimba, okubangela ukulimala okukhulu kwezitho nokuvuvukala.
I-Hypotension kanye nokugcinwa koketshezi: Njengomphumela wama-cytokines akhishwa amaseli e-CAR T, ezinye iziguli zingase zibe nomfutho wegazi ophansi (hypotension) nokugcinwa koketshezi. Ukubhekana nalezi zimpawu, kungase kudingeke izinyathelo ezisekelayo ezihlanganisa uketshezi olufakwa emthanjeni nezidakamizwa.
Izifo Zesibili: Imibiko yezifo zesibili ezibulalayo ezivela ngemva kokwelashwa kwe-CAR T-cell ikhona, kungakhathaliseki ukuthi inqabile. Njengamanje ucwaningo luyenziwa mayelana namathuba ezifo zesibili kanye nezingozi zesikhathi eside.

Kubalulekile ukukhumbula ukuthi akusona sonke isiguli esizoba nale miphumela engemihle, nokuthi izinga lomuntu ngamunye lokuzwela lizohluka. Ukuze kuncishiswe futhi kuncishiswe le miphumela emibi engaba khona, ithimba lezokwelapha lihlolisisa iziguli ngaphambi, phakathi, nangemuva kokwelashwa kwe-CAR T-cell.

Ubude besikhathi

Bheka ngezansi kwengqikithi yesikhathi esidingekayo ukuze uqedele inqubo yokwelapha ye-CAR T-Cell. Nakuba isikhathi sincike kakhulu ebangeni lelebhu esuka esibhedlela elungise i-CAR.

Ukuhlolwa nokuhlolwa: isonto elilodwa
Ukwelashwa kwangaphambili & Ukuqoqwa kwe-T-Cell: isonto elilodwa
Ukulungiswa kwe-T-Cell nokubuyisela: amasonto amabili-amathathu
Ukuhlaziywa kwe-1st Ukusebenza kahle: amaviki amathathu
Ukuhlaziywa kwe-2nd Ukusebenza kahle: amaviki amathathu.

Isikhathi esiphelele: 10-12 Amaviki

Singakusiza Kanjani Ukuthola Ukwelashwa Okungcono Kakhulu Komdlavuza eNdiya?

Ukuthola ukwelashwa okungcono kakhulu komdlavuza eNdiya kungaba nzima kakhulu, ikakhulukazi uma ukhathazekile ngezindleko kanye nekhwalithi. Yilapho iCancerFax ingakuqondisa khona njengomngane weqiniso!

Siyazi ukuthi impilo yakho ibaluleke kakhulu nokuthi ukubeka engcupheni izinga lokunakekelwa akuyona inketho. Kungakho sikhethe ngokucophelela odokotela abanolwazi olunzulu futhi sabambisana nezibhedlela ezimbalwa ezindaweni zamanani ahlukahlukene ukuze uthole okulingana kahle kakhulu nezidingo zakho. Ngale ndlela, ungathola ukunakekelwa okuhle kakhulu ngaphandle kokuphula ibhange. Kule minyaka engu-10 edlule, indlela yethu isisize kakade iziguli ezivela emazweni amakhulu angaphezu kuka-8, futhi sizimisele ukukwenzela okufanayo. Sithembe ukuthi sizothola ukwelashwa okungcono kakhulu kwe-CAR T Cell eNdiya.

Inqubo Elula Kakhulu Yokuthola I-CAR T Cell Therapy E-India

Thumela Imibiko Yakho

Yabelana ngomlando wakho wezokwelapha, okuhlanganisa imibiko yakamuva yegazi, imiphumela ye-biopsy, nama-PET scan, nathi ku-info@cancerfax.com. Lesi sinyathelo esibalulekile sisivumela ukuthi sihlole isimo sakho futhi sikuqondise ekutholeni ukwelashwa okufanele kakhulu.

Ukuhlola Nombono

Ithimba lethu lochwepheshe lizobuyekeza imibiko yakho ngokucophelela ukuze likunikeze ukuhlola okuphelele kanye nombono wochwepheshe. Lokhu kusisiza ukuthi sinqume inkambo engcono kakhulu futhi sincome izibhedlela kanye nochwepheshe abafaneleka kakhulu bokwelashwa kwe-CAR T Cell yakho ngokwesabelomali sakho.

I-Visa Yezokwelapha Nokuhamba

Sizokusiza ekutholeni i-visa yezokwelapha futhi sizokuhlela namalungiselelo akho okuhamba. Inhloso yethu ukwenza uhambo lwakho lube lula ngangokunokwenzeka ukuze ukwazi ukugxila ekwelashweni nasekululameni kwakho.

Ukwelashwa Nokulandelela

Uma usufike esibhedlela ozikhethele sona, ithimba lethu elizinikele lizoqhubeka nokukusiza kulo lonke uhlelo lokwelashwa. Sikhuthaza ukuxhumana okungenazihibe phakathi kwakho nabasebenzi bezokwelapha, siqinisekisa ukuthi uthola ukwelashwa okungcono kakhulu. Inhlalakahle yakho isalokhu ihamba phambili kithi.

Imibuzo Evame Ukubuzwa NgeCar T-Cell Therapy E-India

Iyini i-CAR T-cell therapy?
- I-CAR T-cell therapy iwuhlobo lwe-immunotherapy olubandakanya ukulungisa ama-T cell esiguli ukuze abone futhi ahlasele amangqamuzana omdlavuza. Lokhu kwelashwa komuntu siqu kubonise imiphumela ethembisayo ezinhlotsheni ezithile zomdlavuza.
Ingabe i-CAR T-cell therapy iyatholakala eNdiya?
- Yebo, i-CAR T-cell therapy iyatholakala eNdiya kwezinye izikhungo ezikhethekile zomdlavuza. Nokho, ukutholakala kwayo kungase kuhluke, futhi kungase kukhawulelwe ezinhlotsheni ezithile zomdlavuza.
Yimuphi umdlavuza ongelashwa nge-CAR T-cell therapy eNdiya?
- Kusukela ekubuyekezweni kwami kokugcina, ukwelashwa kwe-CAR T-cell kwakusetshenziselwa ikakhulukazi ukwelapha izinhlobo ezithile zomdlavuza wegazi, njenge-leukemia ne-lymphoma. Imidlavuza ethile efanelekela ukwelashwa ingase incike ezimisweni ezilandelwa izikhungo zokunakekelwa kwezempilo ngazinye.
Ziyini izindleko zokwelashwa kwe-CAR T-cell eNdiya?
- Izindleko zokwelashwa kwe-CAR T-cell zingaba phezulu. Ingase ihlanganise izindleko zokuqoqa nokulungisa ama-T cell esiguli, izinqubo zaselabhorethri, kanye nokuphathwa kokwelashwa. Izindleko zingahluka kuye ngohlobo lomdlavuza owelashwayo kanye nesikhungo sezempilo.
Ingabe ikhona imiphumela emibi yokwelashwa kwe-CAR T-cell?
- Yebo, njenganoma yikuphi ukwelashwa, i-CAR T-cell therapy ingaba nemiphumela engemihle. Imiphumela emibi evamile ihlanganisa i-cytokine release syndrome (CRS) kanye nobuthi be-neurologic. Ubukhulu bemiphumela engemihle bungahluka phakathi kwabantu.
Iphumelele kangakanani i-CAR T-cell therapy ekwelapheni umdlavuza?
- I-CAR T-cell therapy ibonise impumelelo emangalisayo ekwelapheni izinhlobo ezithile zomdlavuza, ikakhulukazi umdlavuza wegazi. Kodwa-ke, ukusebenza kwayo kungahluka kuye ngohlobo nesigaba somdlavuza, kanye nezici zesiguli ngasinye.
Ingabe i-CAR T-cell therapy imbozwa umshwalense eNdiya?
- Ukufakwa komshwalense kungahluka. Kubalulekile ukuthi uhlole umhlinzeki womshwalense kanye nesikhungo sokunakekelwa kwezempilo esinikeza ukwelashwa ukuze uqonde izinketho zokuhlinzeka.
Ngingafinyelela kanjani ekwelashweni kwe-CAR T-cell eNdiya?
- Iziguli ezinentshisekelo yokwelashwa kwe-CAR T-cell kufanele zithintane nodokotela be-oncologists nabahlinzeki bezempilo abagxile kulokhu kwelashwa. Bangakwazi ukuqondisa iziguli ngenqubo yokuhlola futhi banqume ukufaneleka.